Direct thrombin inhibitors for the treatment of venous thromboembolism: Analysis of the dabigatran versus warfarin clinical trial

Seminars in Vascular Surgery

Volumn 24, Issue 3, 2011, Pages 157-161

  Liem, Timothy K ^a   DeLoughery, Thomas G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; LEG THROMBOSIS; LIVER TOXICITY; LONG TERM CARE; LUNG EMBOLISM; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; STROKE; STUDY DESIGN; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 83455219511     PISSN: 08957967     EISSN: 15584518     Source Type: Journal    
DOI: 10.1053/j.semvascsurg.2011.11.003     Document Type: Article

References (20)

1. Stahmann M.A., Huebner C.H., Link K.P. Studies on the hemorrhagic sweet clover disease. V. identification and synthesis of the hemorrhagic agent. J Biol Chem 1941, 138:513-527.
2. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425-1434.
3. Kearon C., Ginsber J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349. 631369.
4. Fiessinger J.N., Huisman M.V., Davidson B.L., et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. JAMA 2005, 293:681-689.
5. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral dabigaran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
6. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
7. Eriksson B.I., Dahl O.E., Huo M.K., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost 2011, 105:721-729.
8. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
9. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
10. Schulman S., Rhedin A.S., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therpay after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661-1665.
11. Prandoni P., Noventa F., Ghirarduzzi A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007, 92:199-205.
12. th edition). Chest 2008, 133(suppl):454S-545S.
13. Stangier J., Eriksson B.I., Dahl O.E., et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005, 45:555-563.
14. Stangier J., Rathgen K., Stähle H., et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-center study. Clin Pharmacokinet 2010, 49:259-268.
15. Shah S.V., Gage B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, 123:2562-2570.
16. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
17. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
18. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
19. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in pateints with atrial fibrillation. N Engl J Med 2011, 365:981-992.
20. Buller H., Beitchman D., Prins M., et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008, 6:1313-1318.